JNK
Entity Detail — Knowledge Graph Node
Understanding Entity Pages
This page aggregates everything SciDEX knows about JNK: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Summary
JNK is a protein involved in neurodegeneration research. Key relationships include: interacts with, activates, regulates. Associated with AD, ALI, ALS. Connected to 881 entities in the SciDEX knowledge graph.
AI-generated illustration
Regenerate portrait ↻| Gene Symbol | JNK |
| Chromosome | MAPK8: 10q11.22, MAPK9: 5q35.1, MAPK10: 4q21.3 |
| Protein Type | Kinase |
| Function | Upstream activation: Stress signals (UV radiation, oxidative stress, inflammatory cytokines) activate MAPKKKs such as MEKK1, MLK3, and TAK1 |
| Molecular Weight | ~46-48 kDa per isoform |
| Pathways | Akt, Apoptosis, Autophagy, Differentiation, Ferroptosis |
| GeneCards | JNK |
| Human Protein Atlas | JNK |
| Microglial neuroinflammation | p38α drives TNF-α, IL-1β, and IL-6 production in activated microglia surrounding dopaminergic neurons [@p38micro] |
| Neuronal survival | p38 inhibition protects against oxidative stress and mitochondrial dysfunction in substantia nigra neurons |
| BBB penetration | Losmapimod has demonstrated CNS exposure in multiple clinical trials (FSHD, ALS), addressing a key challenge for CNS kinase inhibitors |
| Synergy potential | Combined with standard dopaminergic therapies, p38 inhibition may provide disease-modifying neuroprotection |
| FSHD Phase 3 (NCT04060468) | Completed, established safety in >600 patients with facioscapulohumeral muscular dystrophy |
| ALS Phase 2b (NCT04988915) | Ongoing, evaluating losmapimod's effects on functional decline [@losmapi] |
| Safety profile | Generally well-tolerated with >1,000 patients treated across indications; liver function monitoring required |
| Associated Diseases | AD, Aging, ALI, Als, Alzheimer |
| Known Drugs/Compounds | ANTHOCYANINS, NAC, N-ACETYLCYSTEINE, Palmitic Acid, Quercetin, rapamycin |
| Interactions | 6-OHDA, ABCD3, ACC, AD, AGING, AIM2 |
| KG Connections | 2249 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Wiki Pages (15)
Knowledge base pages for this entity
JNK/p38 MAPK Inhibitor Companies for Parkinson's Disease
company · 2217 wordsJNK/p38 MAPK Signaling Pathway in Neurodegeneration
mechanism · 2736 wordsJNK1 (MAPK8)
gene · 1540 wordsJNK/p38 MAPK Signaling in Neurodegeneration
mechanism · 1516 wordsJNK1 Protein
protein · 1361 wordsJNK3 (MAPK10)
gene · 1192 wordsPathway Diagram
graph TD
JNK["JNK"]
JNK -->|"activates"| RB1CC1_nuclear_translocation["RB1CC1 nuclear translocation"]
JNK -->|"activates"| apoptosis["apoptosis"]
JNK -->|"activates"| c_Jun["c_Jun"]
JNK -->|"regulates"| neurodegeneration["neurodegeneration"]
JNK -->|"regulates"| gliosis["gliosis"]
JNK -->|"activates"| Aging["Aging"]
JNK -->|"interacts"| Alzheimer["Alzheimer"]
JNK -->|"interacts"| ALS["ALS"]
JNK -->|"interacts"| Frontotemporal_Dementia["Frontotemporal Dementia"]
JNK -->|"interacts"| Dementia["Dementia"]
JUN["JUN"] -->|"regulates"| JNK
MTOR["MTOR"] -->|"regulates"| JNK
LTBR["LTBR"] -->|"inhibits"| JNK
HSPA1A["HSPA1A"] -->|"regulates"| JNK
ROS["ROS"] -->|"inhibits"| JNK
APOPTOSIS["APOPTOSIS"] -->|"inhibits"| JNK
OXIDATIVE_STRESS["OXIDATIVE STRESS"] -->|"inhibits"| JNK
ERK["ERK"] -->|"inhibits"| JNKOutgoing (1370)
| Target | Relation | Type | Str |
|---|---|---|---|
| Als | activates | disease | 1.00 |
| P38 | activates | gene | 1.00 |
| JUN | activates | gene | 1.00 |
| Inflammation | inhibits | disease | 1.00 |
| Inflammation | activates | disease | 1.00 |
| Nf-Κb | activates | pathway | 1.00 |
| Mapk | inhibits | pathway | 1.00 |
| INFLAMMATION | inhibits | gene | 1.00 |
| AKT | activates | gene | 1.00 |
| Neurodegeneration | activates | disease | 1.00 |
| Tumor | activates | disease | 1.00 |
| Cancer | therapeutic_target | disease | 1.00 |
| Mapk | activates | pathway | 1.00 |
| Apoptosis | activates | pathway | 1.00 |
| Pi3K/Akt | activates | pathway | 1.00 |
| CANCER | therapeutic_target | gene | 1.00 |
| JUN | inhibits | gene | 1.00 |
| Apoptosis | regulates | pathway | 1.00 |
| Cancer | inhibits | disease | 0.95 |
| Tumor | therapeutic_target | disease | 0.95 |
| Als | therapeutic_target | disease | 0.95 |
| Neuroinflammation | activates | disease | 0.95 |
| ZBP1 | upregulates | gene | 0.90 |
| MAPK signaling | participates_in | pathway | 0.90 |
| RB1CC1 nuclear translocation | activates | phenotype | 0.90 |
| MAPK | associated_with | pathway | 0.90 |
| apoptosis pathway | participates_in | pathway | 0.90 |
| oxidative stress response | participates_in | pathway | 0.90 |
| Oxidative Stress | activates | pathway | 0.90 |
| DNA | activates | gene | 0.90 |
| Nf-Κb | inhibits | pathway | 0.90 |
| Toll-Like Receptor | activates | pathway | 0.90 |
| NF-ΚB | activates | gene | 0.90 |
| MTOR | activates | gene | 0.90 |
| P38 | inhibits | gene | 0.90 |
| ZBP1 | activates | protein | 0.88 |
| Depressive-Like Behavior | mediates | phenotype | 0.88 |
| Tumor | inhibits | disease | 0.85 |
| Nrf2 | suppresses | protein | 0.85 |
| Als | inhibits | disease | 0.85 |
| Cancer | activates | disease | 0.85 |
| Inflammation | regulates | disease | 0.85 |
| Neurodegeneration | associated_with | process | 0.85 |
| Parkinson | activates | disease | 0.85 |
| unfolded protein response | participates_in | pathway | 0.80 |
| BECN1 | upstream_of | protein | 0.80 |
| Anti-apoptotic Proteins | downregulates | protein | 0.80 |
| apoptosis | activates | phenotype | 0.80 |
| p38 MAPK | part_of | pathway | 0.80 |
| ROS | regulates | gene | 0.80 |
Incoming (914)
| Source | Relation | Type | Str |
|---|---|---|---|
| ROS | activates | gene | 1.00 |
| ERK1 | activates | gene | 1.00 |
| ERK | activates | gene | 1.00 |
| NEURODEGENERATION | activates | gene | 1.00 |
| PI3K | activates | gene | 1.00 |
| APOPTOSIS | activates | gene | 1.00 |
| C-JUN | activates | gene | 1.00 |
| ERK | inhibits | gene | 1.00 |
| TNF | activates | gene | 1.00 |
| NUPR1 | inhibits | gene | 0.95 |
| SP600125 | inhibits | drug | 0.90 |
| NF-ΚB | inhibits | gene | 0.90 |
| TNF | inhibits | gene | 0.90 |
| OXIDATIVE STRESS | activates | gene | 0.90 |
| IRE1 | activates | protein | 0.88 |
| MKK7 | phosphorylates | protein | 0.85 |
| Palmitic Acid | activates | compound | 0.85 |
| HSPA5 | regulates | entity | 0.85 |
| ANTHOCYANINS | inhibits | compound | 0.80 |
| MKK7 | activates | gene | 0.80 |
| P75NTR | activates | protein | 0.80 |
| DUSP8 | associated_with | gene | 0.80 |
| GSTP1 | modulates | protein | 0.80 |
| quercetin | binds_to | drug | 0.80 |
| JUN | regulates | protein | 0.80 |
| APOPTOSIS | inhibits | gene | 0.80 |
| ROS | inhibits | gene | 0.80 |
| OXIDATIVE STRESS | inhibits | gene | 0.80 |
| ERK | therapeutic_target | gene | 0.80 |
| APOPTOSIS | therapeutic_target | gene | 0.80 |
| C-JUN | inhibits | gene | 0.80 |
| ERK | regulates | gene | 0.80 |
| PI3K | therapeutic_target | gene | 0.80 |
| CYTOKINES | inhibits | gene | 0.80 |
| APOPTOSIS | regulates | gene | 0.80 |
| C-JUN | associated_with | gene | 0.80 |
| Quercetin | interacts_with | compound | 0.75 |
| ALZHEIMER | interacts_with | gene | 0.70 |
| AMPK | regulates | gene | 0.70 |
| FIP200 | regulates | gene | 0.70 |
| EIF2AK3 | regulates | gene | 0.70 |
| ERN1 | regulates | gene | 0.70 |
| ALZHEIMER | activates | disease | 0.70 |
| NF-ΚB | activates | gene | 0.70 |
| DDIT3 | regulates | gene | 0.70 |
| BAX | therapeutic_target | gene | 0.70 |
| MTOR | regulates | protein | 0.70 |
| LRP1 | regulates | gene | 0.70 |
| BAX | activates | gene | 0.70 |
| TLR4 | activates | gene | 0.70 |
Targeting Hypotheses (0)
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| No targeting hypotheses | |||
Mentioning Analyses (4)
Scientific analyses that reference this entity
Gene expression changes in aging mouse brain predicting neurodegenerative vulner
neurodegeneration | 2026-04-03 | 42 hypotheses Top: 0.910
Digital biomarkers and AI-driven early detection of neurodegeneration
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.756
Blood-brain barrier transport mechanisms for antibody therapeutics
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration | 2026-04-01 | 11 hypotheses Top: 0.920
Experiments (0)
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Related Papers (0)
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Debates (4)
Multi-agent debates referencing this entity
Investigate how lipid raft composition (cholesterol metabolism, sphingolipids) c
closed · Rounds: 5 · Score: 0.93 · 2026-04-11
Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi
closed · Rounds: 4 · Score: 0.91 · 2026-04-06
Can speech, gait, retinal imaging, sleep, and smartphone data detect neurodegene
closed · Rounds: 4 · Score: 0.95 · 2026-04-06
What gene expression changes in the aging mouse brain predict neurodegenerative
closed · Rounds: 4 · Score: 0.95 · 2026-04-03
Related Research
Hypotheses and analyses mentioning JNK in their description or question text
No additional research found